.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 4,804,652

« Back to Dashboard

Details for Patent: 4,804,652

Title: Mucopolysaccharides having biological properties, preparation and application thereof as drugs
Abstract:Mucopolysaccharides biologically active and more specific than heparin, particularly with respect to the blood factor Xa. These mucopolysaccharides may be obtained by partial depolymerization, under controlled conditions, of heparin, by the action of a chemical agent such as nitrous acid. The conditions implemented allow the preparation of mucopolysaccharides having a USP titer lower than that of the starting heparin and a Yin-Wessler titer at least equal to that of said heparin. These products may be used particularly as antithrombotic drugs.
Inventor(s): Lormeau; Jean-Claude (Maromme, FR), Petitou; Maurice (Paris, FR), Choay; Jean (Paris, FR)
Assignee: Choay S.A. (Paris, FR)
Filing Date:Feb 19, 1985
Application Number:06/702,509
Claims:1. A process for making mucopolysacharide heparinic fractions which have the L-iduronosyl-2-O-sulfate-(1-alpha-4)-N-sulfo-D-glucosamine-6-O-sulfate disaccharide structural units of heparin with the O-sulfated iduronic components of herparin, which mucopolysaccharide fractions do not differ from heparin with respect to the unsulfated iduronic acid component and are further defined by having a terminal structure as follows ##STR6## wherein R.sub.1, is selected from the group consisting of aldehyde, alcohol and carboxylic acid and R.sub.2 is selected from the group consisting of hydrogen and --SO.sub.3, said mucopolysaccharides having a high and improved antithrombotic activity as measured by anti-X.sub.a activity determined by the Yin Wessler test (YW) as compared to heparin, and a YW/USP ratio of at least 2, which comprises the step of partially depolymerizing heparinic chains having a molecular weight in the range of about 2,000 to about 50,000 daltons by contacting said herparinic chains with nitrous acid in an aqueous medium at a temperature in the range from about 0.degree. C. to about ambient temperature, and at a pH in the range of about 2 to 3, discontinuing the polymerization when the mucopolysaccharides have reached a molecular weight in the range of about 2,000 to about 8,000 daltons by adjusting the pH to a pH outside the depolymerization range of about 2 to 3 and separating the mucopolysaccharides having said terminal structure and which do not differ from heparin with respect to the amount of the unsulfated iduronic acid component.

2. The process of claim 1 wherein the depolymerization is stopped by adjusting the pH to an alkaline pH.

3. The process of claim 2 wherein the pH is adjusted to an alkaline pH with an alkaline agent which is sodium hydroxide.

4. The process of claim 1 wherein the nitrous acid is generated in situ from a derivative selected from the group consisting of a salt and an ether salt.

5. The process of claim 4 wherein the nitrous acid is generated by the addition of an acid which has a physiologically acceptable anion.

6. The process of claim 5 wherein the acid is hydrochloric acid.

7. The process of claim 4 wherein the final concentration of heparin is from about 1 to about 10 g per 100 ml of reaction medium and the concentration of sodium nitrite is from about 0.02M to 0.1M.

8. The process of claim 7 wherein the concentration of heparin is about 2 g per 100 ml of reaction medium and the concentration of sodium nitrite is about 0.05M.

9. The process of claim 4 wherein the reaction is carried out at a temperature of from about 0.degree. C. to about 10.degree. C.

10. The process of claim 4 wherein the salt is an alkaline earth salt.

11. The process of claim 10 wherein the alkaline salt is sodium nitrite.

12. The process of claim 1 wherein the pH is increased to about 7.5.

13. The process of claim 1 wherein alcohol is added in a proportion of about at least 5 volumes with respect to the volume of the reaction medium to separate the mucopolysaccharide fractions.

14. A process according to claim 1 which further comprises reducing the recovered polysaccharide fragments recovering polysaccharide fragments having terminal structures which are 2,5-anhydro-D-mannitol groups.

15. The process of claim 14 wherein the reducing agent is potassium borohydride.

16. A process according to claim 1 which further comprises oxidizing the recovered polysaccharide fragments recovering polysaccharide fragments having terminal structures which are 2,5-anhydro-D-mannonic acid groups and their pharmaceutically acceptable salts.

17. The process of claim 16 wherein the oxidizing agent is potassium permanganate.

18. Mucopolysaccharide heparinic fractions which have the L-iduronosyl-2-O-sulfate-(1-alpha-4)-N-sulfo-D-glucosamine-6-O-sulfate disaccharide structural units of heparin with the O-sulfated iduronic component of heparin, which mucopolysaccharide heparinic fractions do not differ from heparin with respect to the unsulfated iduronic acid component and are further defined by having a terminal structure as follows ##STR7## wherein R.sub.1 is selected from the groups consisting of an alcohol, an aldehyde and a carboxylic acid and R.sub.2 is selected from the group consisting of hydrogen and --SO.sub.3, which fractions have a molecular weight in the range of about 2,000 to 8,000 daltons and the physiologically acceptable salts therof.

19. The mucopolysaccharide heparinic fractions of claim 18 wherein fractions have R.sub.2 which is hydrogen and R.sub.1 is selected from the specified groups.

20. The mucopolysaccharide haparinic fractions of claim 19 wherein fractions have R.sub.2 which is hydrogen and R.sub.1 is an aldehyde radical.

21. The mucopolysaccharide heparinic fractions of claim 19 wherien fractions have R.sub.2 which is hydrogen and R.sub.1 is --CH.sub.2 OH or aldehyde.

22. The mucopolysaccharide heparinic fractions of claim 19 wherein R.sub.1 is COOH and R.sub.2 is --SO.sub.3.

23. The mucopolysaccharide heparinic fractions of claim 22 which have a ratio of anti-Xa to USP titers of at least 6.

24. The mucopolysaccharide fractions of claim 22 which have an anti-Xa titer of over about 200 units/mg and a ratio of titers of anti-Xa to USP of at least 3.

25. Partially nitrous acid depolymerized heparin products having fragments which have a 2,5-anhydro-D-mannose terminal structure and a --SO.sub.3 primary alcohol function in the 6-position, which products have a Yin-Wessler activity from about 200 IU/mg to about 270 IU/mg.

26. The partially nitrous acid depolymerized heparin products of claim 25 which have a YW/USP ratio of about 10 to about 22.

27. Partially nitrous acid depolymerized heparin products having fragments which have a 2,5-anhydro-D-mannitol terminal structure and a --SO.sub.3 primary alcohol function in the 6-position, which products have a Yin-Wessler activity from about 200 IU/mg to about 270 IU/mg.

28. Partially nitrous acid depolymerized heparin products having fragments which have a 2,5-anhydro-D-mannonic acid terminal structure and a --SO.sub.3 primary alcohol function in the 6-position, which products have a Yin-Wessler activity from about 200 IU/mg to about 270 IU/mg.

29. The mucopolysaccharide heparinic fractions of claims 27 or 28 which is soluble in a water-ethanol medium having a titer of 55-61.degree. GL.

30. A biological composition which has anti-thrombotic activity higher then that of heparin which has increased selective inhibition of the X.sub.a factor in vitro and in vivo, which composition comprises a therapeutically acceptable carrier and in a therapeutically effective amount, a mucopolysaccharide of claims 18, 19, 20, 21, 22, 25, 26, 27 or 28.

31. A therapeutic method for controlling thrombosis in a patient which comprises administering to said patient a biological composition of claim 30 and controlling thrombosis by inhibiting coagulation factor Xa.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc